Display options
Cite
Eylem E, Yahya B, Ozlen B, et al. Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practice. Int J Clin Exp Med. 2015;8(9):16334-9
Eylem, E., Yahya, B., Ozlen, B., Umit, M., Gursel, G., Ayse, I., Haluk, D., Salih, A., Hakan, G., Nilgun, S., Ibrahim, H., & Osman, O. (2015). Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practice. International journal of clinical and experimental medicine, 8(9), 16334-9.
Eylem, Eliacik, et al. "Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practice." International journal of clinical and experimental medicine vol. 8,9 (2015): 16334-9.
Eylem E, Yahya B, Ozlen B, Umit M, Gursel G, Ayse I, Haluk D, Salih A, Hakan G, Nilgun S, Ibrahim H, Osman O. Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practice. Int J Clin Exp Med. 2015 Sep 15;8(9):16334-9. eCollection 2015. PMID: 26629153; PMCID: PMC4659041.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Sep 15;8(9):16334-9. eCollection 2015.

Not all anti-T lymphocyte globulin preparations are suitable for use in aplastic anemia: significantly inferior results with jurkat cell-reactive anti-T lymphocyte globulin in clinical practice.

International journal of clinical and experimental medicine

Eliacik Eylem, Buyukasik Yahya, Bektas Ozlen, Malkan Umit, Gunes Gursel, Isik Ayse, Demiroglu Haluk, Aksu Salih, Goker Hakan, Sayinalp Nilgun, Haznedaroğlu Ibrahim, Ozcebe Osman

Affiliations

  1. Department of Internal Medicine, Hacettepe University Medical School, Division of Hematology Ankara, Turkey.

PMID: 26629153 PMCID: PMC4659041

Abstract

BACKGROUND: Immunosuppressive therapy (IST) with anti-T lymphocyte globulin (ATG) plus cyclosporine (CSA) is standard therapy in patients with non-severe aplastic anemia (AA) in need of treatment and severe aplastic anemia (SAA) who do not have an available HLA-matched donor. The aim of this study was to analyze patients submitted to different ATG preparations as first-line treatment.

PATIENTS AND METHODS: We retrospectively analyzed adult aplastic anemia (AA) patients who received ATG as first-line treatment between 1999 and 2013 to compare hematologic response and survival.

RESULTS: During the time period mentioned 4 different ATG preparations had been used in 38 AA patients (34 severe, 4 non-severe). Responses were better with Lymphoglobulin (6 complete response 1 partial response, 0 refractory disease and 2 death within 3 months after ATG, i.e. during induction), Thymoglobulin (3, 1, 4 and 1, respectively) or ATGAM (1, 2, 1 and 1) compared to the ATG-Fresenius (ATG-F) group (3, 0, 6 and 6) (P = .07). Statistically significant inferior results with ATG-Fresenius (3 complete or partial responses, 6 refractoriness and 6 induction deaths) were evident when other preparations are lumped together (14 complete or partial responses, 5 refractoriness and 4 induction mortalities) (P = .045). Estimated 1 year survival rates were 52.5% versus 76.9%, respectively (P = .13).

CONCLUSIONS: These data support the notion that not all ATG preparations are suitable for use in AA.

Keywords: Aplastic anemia; anti-T lymphocyte globulin; immunosuppressive treatment

References

  1. Exp Hematol. 2006 Jul;34(7):826-31 - PubMed
  2. Zhonghua Xue Ye Xue Za Zhi. 2013 Jan;34(1):30-5 - PubMed
  3. Med Princ Pract. 2011;20(4):341-4 - PubMed
  4. Haematologica. 2011 Sep;96(9):1269-75 - PubMed
  5. Pediatr Hematol Oncol. 2014 Feb;31(1):20-8 - PubMed
  6. Br J Haematol. 1999 Nov;107(2):330-4 - PubMed
  7. J Clin Oncol. 2011 Jun 1;29(16):2230-9 - PubMed
  8. Ann Hematol. 2015 Jun;94(6):947-54 - PubMed
  9. Ann Hematol. 2013 Jun;92(6):817-24 - PubMed
  10. Blood. 2000 Mar 15;95(6):1931-4 - PubMed
  11. J Hematother Stem Cell Res. 2001 Jun;10(3):385-90 - PubMed
  12. Blood. 2006 Oct 15;108(8):2509-19 - PubMed
  13. Haematologica. 2007 Jan;92(1):11-8 - PubMed
  14. Hematology Am Soc Hematol Educ Program. 2007;:23-8 - PubMed
  15. Eur J Haematol. 2010 Feb 1;84(2):154-9 - PubMed
  16. Br J Haematol. 2009 Oct;147(1):43-70 - PubMed
  17. N Engl J Med. 2011 Aug 4;365(5):430-8 - PubMed
  18. Int J Hematol. 2013 Sep;98 (3):319-22 - PubMed
  19. Blood. 2012 Aug 9;120(6):1185-96 - PubMed
  20. Blood. 2012 Jun 7;119(23):5391-6 - PubMed
  21. Exp Hematol. 2014 Jun;42(6):431-8 - PubMed

Publication Types